EUVIMEDEUVIMED entdecken
Leserbrief

Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation

Aun Muhammad Shoro iD, Sufwan Ullah Khan iD

Annals of Pharmacotherapy · 09.08.2026

DOI: 10.1177/10600280261476305 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 09.08.2026. Verfasst von Aun Muhammad Shoro und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

ORCID-Profile: Aun Muhammad Shoro, Sufwan Ullah Khan

Zitieren

APA

Shoro, A. M., & Khan, S. U. (2026). Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261476305

Vancouver

Shoro AM, Khan SU. Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261476305

BibTeX
@article{Shoro2026,
  author = {Shoro, Aun Muhammad and Khan, Sufwan Ullah},
  title = {Bulevirtide (Hepcludex) for Chronic Hepatitis Delta: A Milestone Achievement Demanding Real-World Evaluation},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261476305}
}
Kostenlos starten →